Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today announced a strategic collaboration to...
-Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and devel...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
Belief BioMed announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Adminis...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with b...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease The US Food and Drug Administration (FDA...
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug ...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, announced the d...
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform ...
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult pati...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...
© 2026 Biopharma Boardroom. All Rights Reserved.
